12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GNbAC1: Phase IIa started

GeNeuro began a single-blind, placebo-controlled, Swiss Phase IIa trial to evaluate single ascending-doses of 2 or 6 mg/kg IV GNbAC1...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >